Cemiplimab, sold under the brand name Libtayo, is a monoclonal antibody medication for the treatment of squamous cell skin cancer. [7][8] Cemiplimab belongs to a class of drugs that binds to the programmed death receptor-1 (PD-1), blocking the PD-1/PD-L1 pathway. [6][9]

What is cemiplimab? Cemiplimab is used to treat certain cancers of the skin. Cemiplimab is also used alone or in combination with other cancer drugs to treat lung cancer that has not spread outside your chest.

Healthcare professionals can find information about approved indications for LIBTAYO (cemiplimab-rwlc) along with treatment guidelines and resources. Review Important Safety Information and full Prescribing Information.

Sep 12, 2022 · Cemiplimab, an anti–programmed cell death 1 (PD-1) monoclonal antibody, has been approved for the treatment of metastatic or locally advanced cutaneous squamous-cell carcinoma for which no ...

Cemiplimab is a type of immunotherapy. It is a treatment for advanced cutaneous squamous cell carcinoma (SCC). Find out about how you have it, possible side effects and other important information.

Cemiplimab-rwlc is a type of drug called an immune checkpoint inhibitor (a type of immunotherapy). It is a monoclonal antibody that binds to the protein PD-1 on the surface of immune cells called T cells.

Cemiplimab is also called Libatyo ®. It is a type of immunotherapy drug called a checkpoint inhibitor. Cemiplimab is used to treat a type of skin cancer called squamous cell carcinoma. It …

Oct 19, 2018 · The immunotherapy drug cemiplimab (Libtayo) has been approved by FDA for advanced cutaneous squamous cell carcinoma, a common type of skin cancer.

Jun 4, 2018 · Cemiplimab is a high-affinity, highly potent human monoclonal antibody directed against programmed death 1 (PD-1). 15 In the dose-escalation portion of the phase 1 study of cemiplimab, a deep...

Cemiplimab is a PD-1 immune checkpoint inhibitor and is supplied as a concentrate solution (50 mg/mL) for dilution as 250 mg/5mL and 350 mg/7 mL. The recommended dose of cemiplimab is 350 mg administered as an IV infusion over 30 minutes every 3 weeks.